← Back to News

Partnership Fund portfolio company TARA Biosystems appoints pharmaceutical industry innovation leader, John M. Baldoni, Ph.D., to its Board of Directors

NEW YORKFeb. 20, 2018 /PRNewswire/ — TARA Biosystems, Inc., a company offering physiologically relevant “heart-on-a-chip” tissue models for drug discovery and development applications, announced today that it has appointed pharmaceutical industry innovation leader, John M. Baldoni, Ph.D. to its Board of Directors.

TARA Biosystems offers bioanalytical testing services on its human stem cell-derived cardiac tissue platform. The company’s Biowire™ II platform enables early cardiac risk assessment of drug discovery candidates and accelerates discovery efforts for novel heart medicines via its disease modeling and phenotypic screening capabilities. TARA continues to develop a proprietary analytics platform, leveraging data from internal development programs on its Biowire™ II tissue production platform.

“TARA Biosystems uniquely enables the production of large amounts of high fidelity human-relevant data,” said Dr. Baldoni. “This provides foundational information for machine learning and next-generation computational approaches that are fundamentally shifting the way drug development is done today.”

Read the full Press Release